Brawn Biotech logo

Brawn Biotech financials: balance sheet, profit and loss, cash flow

BSE: 530207Pharmaceuticals & BiotechnologySmall Cap

Brawn Biotech Limited · Face value ₹10 · Listed May 1995
Last close ₹25.87up ₹0.47 (1.85%)

Share price at the BSE close on 28 Oct 2026. Previous close ₹25.40.

28 Oct: open ₹26.64, high ₹26.64, low ₹25.87

52-week range of traded prices to 28 Oct 2026
₹17.71Low, 16 Feb 2026₹26.64High, 28 Oct 2026
Market cap
₹7.76 Cr4,925th largest listed
P/E
9.04
P/B
1.79
Dividend yield
Nonein the last 12 months
ROE
22.3%
ROCE
−12.6%
Debt to equity
0.00
Volume, BSE
754

Brawn Biotech's financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Brawn Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
611.4Mar 17561.3Mar 18651.30Mar 19500.60Mar 2035−0.60Mar 218.6−1.60Mar 2222−0.90Mar 2316−1.50Mar 2413−1.80Mar 25170.90Mar 26
Peak revenue ₹65 Cr, year to Mar 2019; lowest ₹8.62 Cr, year to Mar 2022Back to profit in the year to Mar 2026, ₹0.94 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
5.5%−23.3%2.0%3.5%1.8%1.5%−1.7%−23.3%−1.4%−9.3%−13.2%−1.9%2.3%2.3%2.0%1.2%−1.6%−19.1%−3.9%−9.4%−13.4%5.5%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue17
  2. Materials and goods−15
  3. Employee costs−0.7
  4. Other expenses−2.1
  5. Operating profit−0.3
  6. Depreciation−0.1
  7. Other income+0.5
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax0.0
  11. Tax+0.9
  12. Net profit0.9

What the company owns

  • Inventory₹10 Cr
  • Plant, investments and other assets₹7 Cr
  • Receivables₹4 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹14 Cr
  • Net worth₹4 Cr
  • Other liabilities₹2 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Brawn Biotech quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 29 MayMar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 13 Aug
Revenue from operations60.555.865.249.635.08.622.216.513.517.017.3
59.353.864.048.935.610.622.518.015.217.317.7
Materials and goods bought52.248.858.542.130.06.619.214.411.914.514.7
Employee costs2.03.03.03.12.41.81.41.41.10.70.8
Other expenses5.12.02.53.73.22.22.02.32.22.12.2
Operating profit before depreciation1.22.01.20.7−0.6−2.0−0.3−1.5−1.8−0.3−0.5
Operating margin2.0%3.5%1.8%1.5%−1.7%−23.3%−1.4%−9.3%−13.2%−1.9%−2.6%
Materials, % of revenue86.2%87.6%89.8%84.9%85.8%76.4%86.3%87.1%88.6%85.5%85.4%
Employee costs, % of revenue3.3%5.3%4.6%6.2%6.8%20.9%6.3%8.5%8.4%4.0%4.5%
Other expenses, % of revenue8.5%3.6%3.8%7.5%9.1%25.9%8.8%13.7%16.2%12.4%12.7%
Depreciation and amortisation0.00.00.00.00.00.10.10.10.10.10.1
Operating profit after depreciation1.21.91.10.7−0.6−2.1−0.4−1.6−1.9−0.4−0.5
Other income0.00.10.70.20.30.00.00.10.10.50.5
Finance costs0.10.10.10.00.00.10.00.00.00.00.0
Profit before one-off items and tax1.22.01.80.8−0.4−2.1−0.4−1.5−1.80.0−0.1
One-off items0.6–0.00.00.00.00.00.00.00.00.0
Profit before tax1.82.01.80.8−0.4−2.1−0.4−1.5−1.80.0−0.1
0.40.70.50.20.2−0.50.50.00.0−0.9−0.9
Net profit1.41.31.30.6−0.6−1.6−0.9−1.5−1.80.90.9
Other comprehensive income––0.10.00.10.10.00.00.00.00.0
Total comprehensive income––1.40.6−0.5−1.6−0.9−1.5−1.81.00.9
Net margin2.3%2.3%2.0%1.2%−1.6%−19.1%−3.9%−9.4%−13.4%5.5%5.0%
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations0.94.11.116.114.725.937.838.646.9
–––––25.237.338.145.4
Materials and goods bought0.73.3–––16.428.234.040.5
Employee costs–––––4.22.81.51.9
Other expenses–––––4.76.32.63.1
Operating profit before depreciation–––––0.70.40.61.5
Operating margin–––––2.7%1.2%1.4%3.2%
Materials, % of revenue–––––63.3%74.6%88.0%86.4%
Employee costs, % of revenue–––––16.1%7.5%3.9%4.0%
Other expenses, % of revenue–––––18.1%16.7%6.6%6.6%
Depreciation and amortisation–0.00.00.00.00.00.00.00.0
Operating profit after depreciation–––––0.70.40.51.5
Other income–––0.00.00.00.70.10.0
Finance costs–––––0.10.10.10.1
Profit before one-off items and tax–0.40.10.80.20.61.00.51.3
One-off items––––––−0.8––
Profit before tax0.10.40.10.80.20.60.20.51.3
Tax0.10.0––0.00.20.10.20.4
Net profit0.00.40.10.80.20.40.10.31.0
Net margin1.0%9.0%5.1%4.8%1.1%1.4%0.3%0.7%2.0%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 29 MayMar 2024Mar 2025Mar 2026
8.79.38.87.26.35.13.44.3
Share capital3.03.03.03.03.03.03.03.0
Reserves5.76.35.84.23.32.10.41.3
Borrowings0.00.00.00.00.00.00.00.0
13.710.94.96.38.06.59.315.2
0.20.10.20.20.23.07.81.3
Total assets22.520.313.913.814.514.620.520.9
0.81.11.11.61.11.43.03.7
21.719.212.712.213.413.117.517.1
Net debt−0.5−0.4−0.4−0.2−0.4−0.4−0.2−0.3
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Filed 29 MayMar 2024Mar 2025Mar 2026
0.030.190.30−0.020.050.11
0.310.190.31−0.020.050.11
0.512.120.651.461.69−0.05
Receivables5.706.74−2.521.37−0.88−0.04
Inventories0.13−4.47−0.07−1.23−4.450.40
Payables−5.881.512.332.037.38−0.25
Other working capital0.57−1.660.90−0.71−0.35−0.17
Tax paid−0.280.00−0.010.000.000.00
Capital spending0.000.300.100.010.240.03
Free cash flow0.03−0.110.21−0.04−0.190.09
Cash from investing0.00−0.30−0.10−0.01−0.24−0.03
−0.04−0.060.010.000.000.00
Dividends paid0.000.000.000.000.000.00
Shares bought back0.000.000.000.000.000.00
Shares issued0.000.000.000.000.000.00
Net change in cash0.00−0.170.21−0.04−0.200.08
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Brawn Biotech dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 29 MayMar 2024Mar 2025Mar 2026
Earnings per share₹4.64₹4.18₹4.63₹2.01–−₹5.25−₹3.04−₹5.14−₹5.87₹3.26
Diluted earnings per share₹4.64₹4.18₹4.63₹2.01–−₹5.25−₹3.04−₹5.14−₹5.87₹3.26
Dividend per share₹1.50₹1.00––––––––
Book value per share––₹28.85₹30.87₹29.31₹24.07₹21.03₹16.89₹11.21₹14.46
Dividend payout32.3%23.4%––––––––
Shareholder yield––––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)20.716.111.15.66.65.25.06.04.96.3
Earnings per share is left blank for the year to Mar 2021: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Standalone, years to March.Brawn Biotech PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 29 MayMar 2024Mar 2025Mar 2026
Revenue growth29.1%−7.9%16.8%−23.9%−29.5%−75.4%157.9%−25.8%−18.4%26.1%
Operating profit growth−19.1%59.2%−40.8%−36.9%––––––
Net profit growth46.5%−7.9%4.0%−55.6%––––––
Earnings per share growth46.4%−9.9%10.8%−56.6%––––––
––15.4%6.6%−6.1%−20.5%−12.8%−27.1%−42.7%24.4%
–––−8.8 pts−12.7 pts−14.4 pts7.7 pts−14.3 pts−15.5 pts67.1 pts
From the net margin–––−6.4 pts−15.3 pts−67.8 pts16.3 pts−17.9 pts−11.6 pts60.4 pts
From asset turnover–––−1.8 pts1.0 pts51.4 pts−6.4 pts8.6 pts12.5 pts1.2 pts
From borrowing–––−0.6 pts1.6 pts2.0 pts−2.2 pts−5.0 pts−16.4 pts5.5 pts
Return on capital employed––13.0%7.5%−7.2%−28.5%−6.5%−32.1%−56.1%−10.3%
Cash conversion–––––––––11.9%
Interest cover18.333.718.414.1––––––
Debt to equity––0.000.000.000.000.000.000.000.00
Receivable days––921109711987869376
Inventory days––23326291153320253
Payable days––657432225123144252362
Cash conversion cycle, days––3039681565595161−33
Working capital days––4258782398113821636
Asset turnover––2.892.322.050.621.571.130.770.82
Assets per rupee of net worth––2.602.391.891.732.092.564.165.37
Sales per rupee of plant––340.01282.23245.7922.3459.6849.4729.2546.57
Capital spending to depreciation––––0.005.570.880.122.110.21
Plant being built, % of plant in use––0.0%––––––0.0%
Interest cover is left blank for the years to Mar 2021, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.5%
Measure10 years5 years3 years
Revenue growth, yearly rate−9.7%−13.5%−8.6%
Profit growth, yearly rate−0.1%––
Return on equity, average–−15.8%−15.1%
Return on capital employed, average–−26.7%−32.9%
Operating margin, average−4.2%−9.8%−8.1%
Net margin, average−3.4%−8.0%−5.7%
Asset turnover, average–0.980.91
Cash conversion cycle, days, average–8774
Debt to equity, average–0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations0.630.140.11
Cash from investing−0.67−0.28−0.03
Cash from financing−0.07−0.010.00
Capital spending0.670.280.03
Dividends paid0.000.000.00
Shares bought back0.000.000.00
Shares issued for cash0.000.000.00
Borrowings raised–0.000.00
Borrowings repaid0.000.000.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––445235
Altman Z-scorePublished threshold 1.81––4.433.814.491.552.561.901.041.24
Beneish M-scorePublished threshold −1.78––––−2.69−4.06−1.48−3.01−2.68−2.37
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−3.42−11.10−7.59−10.36−9.154.13
Receivables growth less revenue growthOur threshold 0 percentage points–––14.99−8.625.64−68.71−1.156.27−22.15
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––42.88−5.281,817.47−189.7150.6790.91−25.57
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−2.01−1.8118.99−7.10−0.094.30−1.09
Assets under construction, years of additionsOur threshold 2 years of additions–––––––––0.00
Effective tax ratePublished threshold 17.16 per cent20.6734.6326.1727.87–––––−93,950.00
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––––––−93,950.00
A threshold marked as ours has no published figure; it is the line we read the check against.